Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

GONZALEZ, CHRISTIAN

NPI: 1912987983 · AVENTURA, FL 33180 · Anesthesiology Physician · NPI assigned 01/18/2006

$1.71M
Total Medicaid Paid
107,508
Total Claims
55,028
Beneficiaries
37
Codes Billed
2018-01
First Month
2024-12
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 11,989 $102K
2019 22,941 $430K
2020 21,266 $467K
2021 24,975 $522K
2022 11,786 $135K
2023 10,849 $54K
2024 3,702 $3K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99233 Prolong inpt eval add15 m 32,704 8,694 $762K
99232 Subsequent hospital care, per day, moderate complexity 14,598 3,712 $221K
99223 Prolong inpt eval add15 m 5,411 4,573 $209K
99255 1,532 1,200 $140K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes 1,099 258 $74K
99231 Subsequent hospital care, per day, straightforward or low complexity 4,263 615 $60K
99222 Initial hospital care, per day, moderate complexity 1,821 1,632 $44K
99309 Subsequent nursing facility care, per day, low to moderate complexity 7,889 5,176 $44K
99254 382 316 $39K
99308 Subsequent nursing facility care, per day, straightforward 12,419 7,507 $38K
99306 Prolong nursin fac eval 15m 3,091 2,623 $27K
99205 Prolong outpt/office vis 344 297 $12K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5,205 4,345 $9K
99215 Prolong outpt/office vis 388 264 $7K
99305 1,302 1,038 $6K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 7,208 6,088 $6K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 258 202 $5K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,303 2,094 $2K
99335 389 247 $2K
L0650 Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf 95 75 $1K
99334 205 148 $738.11
62323 220 192 $634.93
L0637 Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise 23 17 $549.58
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 673 613 $322.83
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 1,590 1,316 $321.47
99336 340 238 $171.54
99307 159 119 $114.98
20610 27 24 $44.07
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 232 208 $1.98
99349 318 268 $0.00
80305 251 243 $0.00
77002 27 24 $0.00
99358 Prolong nursin fac eval 15m 82 59 $0.00
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 428 407 $0.00
99348 172 139 $0.00
96138 34 31 $0.00
G0452 Molecular pathology procedure; physician interpretation and report 26 26 $0.00